Biomarker & Intervention Discovery
Alopecia Areata
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs2.23MWHO GHE 2021 · all ages
Global DALYs41.44MWHO GHE 2021 · worldwide
US mortality6,479 deaths/yrWHO GHE 2021
Global mortality92.1K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionPatchy AA: spontaneous regrowth in 50-80% within 1 year; alopecia totalis/universalis (AT/AU): spontaneous full…
Best-intervention remissionBaricitinib (Olumiant): 38.8% achieving ≥80% scalp coverage (SALT score ≤20) at 36 weeks vs 2% placebo (BRAVE-AA1)…
Gap sizeVery large — JAK inhibitors are transformative but no approved treatment existed before June 2022; most patients…
Primary barrieraccess
Full remission profile →
Remission & chronicity
Spontaneous remission
Patchy AA: spontaneous regrowth in 50-80% within 1 year; alopecia totalis/universalis (AT/AU): spontaneous full regrowth <10%; chronic AA (>10 years): spontaneous remission rare
Best-intervention remission
Baricitinib (Olumiant): 38.8% achieving ≥80% scalp coverage (SALT score ≤20) at 36 weeks vs 2% placebo (BRAVE-AA1); ritlecitinib (Litfulo): 23.4% SALT ≤10 at 24 weeks (ALLEGRO); dupilumab: negative Phase 3 for AA (not effective despite positive for AD)
Gap size
Very large — JAK inhibitors are transformative but no approved treatment existed before June 2022; most patients previously managed with immunosuppressants with low efficacy and side effects
Baricitinib (2022) and ritlecitinib (2023) are the first approved treatments specifically for severe AA; prior to this, intralesional corticosteroids and systemic immunosuppressants (cyclosporine, methotrexate) provided variable and non-durable response; cost ($20-25K/year) and durability questions on treatment cessation are key barriers
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Alopecia Areata” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."